21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
Related Articles
Upcoming FDA-AACR Workshop Will Discuss DPD Deficiency Testing
A FDA-AACR workshop will discuss the considerations for DPD deficiency testing before chemotherapy with fluoropyrimidines.
How a Hospital Chain Used a Poor Neighborhood to Turn Huge Profits (Published 2022)
Bon Secours Mercy Health, a major nonprofit health system, used the poverty of Richmond Community Hospital’s patients to tap into a lucrative federal drug program.
Group 6
This year’s HCC Day on the 27th February 2025 will take place in Bern, Switzerland and can be joined online as well. If you want…
Concomitant HIV‐associated plasmablastic lymphoma and visceral leishmaniasis at initial presentation
Click on the article title to read more.
Red Dye #3 is out, and boosters may get RCTs: Why is the evidence to remove a chemical from food LESS THAN the evidence to recommend a medical interventions?
Things we don’t teach well in medical school
USPSTF Recommendation: Screening for Osteoporosis to Prevent Fractures
This 2025 Recommendation Statement from the US Preventive Services Task Force recommends screening for osteoporosis to prevent osteoporotic fractures in women 65 years or older…
Red dye No. 3: FDA bans ingredient from food | CNN
The US Food and Drug Administration has banned the use of red dye No. 3 in food and beverages.
Reimagining Cancer Care for Patients Experiencing Homelessness by Expanding the Traditional Oncology Team | JCO Oncology Practice
Clinical teams and health systems continue to see an increasing number of individuals with cancer experiencing homelessness. Reconsidering how to deliver optimal care to this…
Net Zero is not enough: ratcheting ambition for sustainable health systems through Reduce and Support
Net Zero is the dominant framework for organising health system decarbonisation. Yet throughout Net Zero’s rise to prominence, greenhouse gas emissions have remained on a…
Revoking Authorization for the Use of Red No. 3 in Food/Ingested Drugs
The FDA is revoking the authorization for the use of FD&C Red No. 3 based on the Delaney Clause of the Federal Food, Drug, and…
